Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Laboratories (CLB) Asset Writedowns and Impairment (2023 - 2026)

Core Laboratories filings provide 4 years of Asset Writedowns and Impairment readings, the most recent being $168000.0 for Q1 2026.

  • On a quarterly basis, Asset Writedowns and Impairment rose 394.12% to $168000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $2.4 million, a 3.41% increase, with the full-year FY2025 number at $2.3 million, down 22.88% from a year prior.
  • Asset Writedowns and Impairment hit $168000.0 in Q1 2026 for Core Laboratories, down from $2.2 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $2.2 million in Q4 2025 to a low of -$151000.0 in Q2 2024.
  • Median Asset Writedowns and Impairment over the past 4 years was $593500.0 (2023), compared with a mean of $708200.0.
  • Biggest five-year swings in Asset Writedowns and Impairment: crashed 94.77% in 2025 and later soared 394.12% in 2026.
  • Core Laboratories' Asset Writedowns and Impairment stood at $576000.0 in 2023, then skyrocketed by 216.49% to $1.8 million in 2024, then increased by 22.22% to $2.2 million in 2025, then plummeted by 92.46% to $168000.0 in 2026.
  • The last three reported values for Asset Writedowns and Impairment were $168000.0 (Q1 2026), $2.2 million (Q4 2025), and $34000.0 (Q1 2025) per Business Quant data.